Advent International to Acquire Significant Stake in Suven Pharmaceuticals

December 26, 2022

Advent International has entered into a definitive agreement to acquire a significant stake in Suven Pharmaceuticals from the Jasti family and will make an open offer for an additional 26% of public shares. Advent plans to evaluate a merger of its CDMO and API platform company, Cohance Lifesciences, with Suven to create a scaled end-to-end CDMO + merchant API powerhouse serving pharma and specialty chemical markets, subject to board and regulatory approvals.

Buyers
Advent International
Targets
Suven Pharmaceuticals
Sellers
Jasti family
Platforms
Cohance Lifesciences
Industry
Pharmaceuticals
Location
Telangana, India
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.